Re:$6.96B was raised by private longevity companies in 2022
by jjk166 on Friday January 27, 2023 @04:52PM
(#34552395)
That's because monoclonal antibodies are targeted to a very specific protein. Polyclonal antibodies which can be used more generally are much cheaper. You're paying for the purity, not the substance.
[ Parent
| on HN ]
There are no comments on this comment yet.